Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Zepatier

- PMLiVE

Olysio leads charge at J&J but competition is on the way

CEO Gorsky warns that Gilead’s Sovaldi will impact sales of hepatitis C drug

- PMLiVE

US senators seeks answers on Sovaldi pricing

Gilead asked to justify pricing of hepatitis drug

- PMLiVE

MSD’s Kate Tillett rewarded for healthcare comms excellence

Company's external affairs director wins at Communiqué 2014

- PMLiVE

Janssen-backed report calls on governments to tackle hepatitis C

Report finds that national policies do not adequately address disease

- PMLiVE

Boehringer pulls faldaprevir and exits hepatitis C market

Unable to challenge all-oral options from Gilead and others

Gilead Sciences

Sovaldi stumbles as NICE assesses hep C drug’s price

Gilead must provide much more cost-effectiveness information

- PMLiVE

ADA: Merck launches registry for type 2 diabetes

Will collect information from 20,000 patients across four countries

AbbVie closes in on US approval of all-oral hepatitis C regimen

FDA grants priority review to company’s protease inhibitor ABT-450 regimen

- PMLiVE

Merck agrees $3.85bn deal for hepatitis specialist Idenix

Opens up direct challenge to Gilead

- PMLiVE

Hepatitis C therapies: dawn of a new age

New treatments from the likes of Merck & Co, Janssen and Gilead offer significant treatment advances

EU flag

EU approval for J&J’s hepatitis C drug

Olysio can be used in combination with Gilead’s Sovaldi

- PMLiVE

Merck’s first-in-class Zontivity cleared in US

FDA approves the protease-activated receptor-1 antagonist to reduce heart attack risk

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links